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Abstract
Background. Haemodialysis patients need sustained
treatment with intravenous iron because iron defi-
ciency limits the efficacy of recombinant human
epoetin therapy in these patients. However, the optimal
intravenous iron maintenance dose has not been
established yet.
Methods. We performed a prospective multicentre
clinical trial in iron-replete haemodialysis patients to
evaluate the efficacy of weekly low-dose (50mg)
intravenous iron sucrose administration for 6 months
to maintain the iron status, and to examine the effect
on epoetin dosage needed to maintain stable haemo-
globin values in these patients. Fifty patients were
enrolled in this prospective, open-label, single arm,
phase IV study.
Results. Forty-two patients (84%) completed the
study. After 6 months of intravenous iron sucrose
treatment, the mean ferritin value showed a tendency
to increase slightly from 405 159 at baseline to
490 275 mg/l at the end of the study, but iron,
transferrin levels and transferrin saturation did not
change. The haemoglobin level remained stable
(12 1.1 at baseline and 12.1 1.5 g/dl at the end of
the study). The mean dose of darbepoetin alfa could be
reduced from 0.75 to 0.46mg/kg/week; epoetin alfa was
decreased from 101 to 74 IU/kg/week; and the mean
dose of epoetin beta could be reduced from 148 to
131 IU/kg/week at the end of treatment.
Conclusions. A regular 50mg weekly dosing schedule
of iron sucrose maintains stable iron stores
and haemoglobin levels in haemodialysed patients
and allows considerable dose reductions for epoetins.
Low-dose intravenous iron therapy may represent an
optimal approach to treat the continuous loss of iron
in dialysis patients.
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iron sucrose; outcome
Introduction
Iron deficiency is common in haemodialysis patients
and limits the efficacy of treatment with epoetin [1].
Intravenous iron therapy is, therefore, required by
almost all haemodialysis patients receiving epoetin to
achieve the target haemoglobin in the most efficient
way [2,3]. The National Kidney Foundation-Dialysis
Outcomes Quality Initiative (NKF-DOQI) guidelines
and the European Best Practice Guidelines (EBPG)
advocate consistent detection and management of iron
deficiency [4–7]. According to the revised EBPG for the
management of anaemia in patients with chronic renal
failure (2004), the serum ferritin target levels should be
>100 mg/l in all patients, but in practice, it is necessary
to aim for a ferritin target of 200–500mg/l to achieve
this minimum level of 100 mg/l [7]. The new NKF-
DOQI guidelines recommend an even higher minimum
ferritin level of >200 mg/l in haemodialysis patients [5].
The EBPG and the NKF-DOQI guidelines do not
give firm recommendations regarding the optimal dose
and frequency of intravenous iron administration.
Whereas it seems clear that iron-deficient haemo-
dialysis patients need initial iron loading, the
maintenance dosing schedule for iron-replete patients
still needs to be defined [8]. Based on the results from
several studies, a relatively broad dosing range from 25
to 150mg/week has been recommended [8–12]. With
such a broad dosing range there is on the one side
a risk of underdosing and also a risk of iron overload
on the other [13].
The purpose of the present study was to examine
whether a majority of iron-replete haemodialysis
patients (ferritin in the range of 200–500mg/l and
transferrin saturation >20%) could maintain their iron
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status with a regularly applied low dose of intravenous
iron sucrose (50mg weekly). A secondary goal was
to examine whether this iron treatment schedule could
reduce the epoetin requirements.
Methods
Study design
The study was designed as a prospective, open-label, single
arm, multicentre phase IV study and was performed in
accordance with the International Conference of
Harmonisation E3 Good Clinical Practice Guidelines and
in compliance with the Helsinki declaration. Six hospital
dialysis centres participated in the study, and all the local
ethics committees approved the study. Written informed
consent was obtained from all the patients.
The study population consisted of 50 stable maintenance
haemodialysis patients. Male and female patients undergoing
maintenance haemodialysis (2–3 sessions per week), 18–75
years of age, were included. All patients had to be iron-
replete (serum ferritin 200–800 mg/l; transferrin saturation
20–50%) and were required to display haemoglobin con-
centrations between 9.0 and 13.5 g/dl on three successive
occasions in the past 2 months before the study. All study
patients received intravenous iron sucrose, in non-systematic
fashion prior to the study inclusion. All study patients were
also on epoetin therapy. Furthermore, hypertension was
controlled with various blood pressure medications, and
secondary hyperparathyroidism was controlled with phos-
phate binders and vitamin D preparations in all study
subjects. The following criteria excluded the patients from
the study: suspicion of iron overload (ferritin >800mg/l,
transferring saturation >50%), active inflammation or
infection, malignancy, blood transfusions 3 months prior to
and during the study.
Study drug administration
Patients received weekly doses of 50mg of iron sucrose
(Venofer) for a total of 24 doses. Iron sucrose was injected
into the venous limb of the haemodialysis tubing system
(slow intravenous push at a rate of 10mg/min). Iron therapy
was stopped if the serum ferritin level exceeded 800mg/l, but
was resumed when the serum ferritin had decreased below
600 mg/l. Treatment failure was defined as a serum ferritin
level which dropped below 100mg/l despite continuous iron
sucrose treatment.
Study parameters
Demographic baseline data (age, sex, ethnicity, height,
weight and body mass index) were collected at the screening
visit. Concomitant medications were also assessed. The
epoetin dosage was not subjected to a defined treatment
algorithm, but was adjusted in order to maintain the
haemoglobin value that was recorded at inclusion.
The epoetin dosage and application schedule was recorded
throughout the study, and was averaged per month.
Mean monthly baseline epoetin doses were calculated as
the mean value of weeks 12 to 9, weeks 8 to 5 and
weeks 4 to 1.
Iron parameters (serum ferritin, serum iron, transferrin
and transferrin saturation), C-reactive protein (CRP) levels
and haematological parameters (haemoglobin, haematocrit,
red blood cell number and red cell indices (mean cellular
volume, MCV; mean cellular haemoglobin, MCH and mean
cellular haemoglobin concentration, MCHC) were measured
at the screening visit and then monthly, using standard
laboratory procedures.
Statistical analyses
All efficacy parameters were analysed using descriptive
statistics. Data are reported as mean SD. SAS Version
8.02 was the statistical software package used for all data
analyses.
Safety measurements
The safety population included all patients who had received
at least one dose of the study medication. Recurrent events
occurring during haemodialysis (pruritus, leg pain) prior to
study entry were recorded. When these events occurred with
the same intensity during the study, they were not reported as
adverse events. Blood pressure was measured 15min before
and 15min after each iron sucrose injection as a measure
of safety.
Results
The trial population consisted of 28 male and 22
female haemodialysis patients. The mean age was
58.2 12.8 years, the mean weight 72.5 15.4 kg and
the mean body mass index 25.8 4.6 kg/m2. The study
was completed by 42 of the 50 patients (84%). Three
patients (6%) terminated the study earlier because of
renal transplantation; three patients (6%) had to be
withdrawn from the study due to an adverse event
which was not related to the study drug application
(shunt malfunction; gastrointestinal bleeding; haemo-
thorax); one patient (2%) had to be excluded due
to persistently high ferritin values; in one case (2%),
serum ferritin levels dropped below 100 mg/ml despite
treatment with iron sucrose (treatment failure).
Iron parameters
All the patients were iron-replete at the start of the
study. The mean ferritin values were in the optimal
target range of 200–500 mg/l as defined by the EBPG.
Mean ferritin values showed a non-significant trend
to increase (þ17.3%) from 405 159 mg/l at baseline
to 490 275 mg/l at the end of study (Table 1).
The iron and transferrin mean values did not change
significantly, and mean transferrin saturation also did
not change during the whole study period (Table 1).
Together, these data show that iron stores increased
slightly, but there was no sign of iron overload during
the 6-month treatment phase.
CRP mean values were 6.8mg/l at week 0, 7.9mg/l
at week 9, 8.4mg/l at week 17 and 6.4mg/l at week 25.
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These CRP values were in the normal range, indicating
the absence of systemic inflammation and infection
during the study.
Haematological parameters
The mean haemoglobin values did not change from
the baseline screening period to the end of the study
(Table 2). The mean haemoglobin of 12.1 g/dl demon-
strates that the patients were in the target range, as
defined by the EBPG and K/DOQI guidelines. Table 2
also shows the red cell indices. MCV, MCH and
MCHC were in the normal range during the entire
study and did not change significantly.
Epoetin requirement
The changes in epoetin dosage are shown in Table 3.
The monthly doses of the epoetins decreased markedly
from the mean monthly values of weeks 12 to 1
(baseline phase) prior to the study to weeks 21 to 24
(assessment phase). The dosage for the three different
epoetins decreased by 38.5% [darbepoetin alfa
(Aranesp)], 6.3% [epoetin alfa (Eprex)] and 8.3%
[epoetin beta (Recormon)]. To confirm these data, we
calculated the epoetin requirements in relation to the
body weight. The mean dose of darbepoetin alfa was
reduced with the iron treatment from 0.75 to 0.46 mg/
kg/week (38.7%). The mean dose of epoetin alfa was
decreased from 101 to 74 IU/kg/week (26.7%).
For epoetin beta, the mean dose could be reduced
from 148 to 131 IU/kg/week (11.5%) at the end of
treatment.
Safety evaluation
Another objective of this study was the evaluation of
the safety of iron sucrose (Venofer) given at a dosage
Table 1. Iron parameters of study population at baseline and during the 26-week study period
Week Ferritin (mg/l) Iron (mmol/l) Transferrin (g/l) TSAT (%)
Screening 405 159 12.7 3.4 1.7 0.3 29.9 8.1
Week 1 379 178 13.3 4.1 1.7 0.3 31.3 11.8
Week 5 430 194 12.7 4.6 1.7 0.3 30.4 13.1
Week 9 415 157 12.9 4.5 1.7 0.3 31.0 10.9
Week 13 420 170 13.5 5.1 1.7 0.3 31.8 13.5
Week 17 426 185 12.7 3.9 1.7 0.3 30.1 9.7
Week 21 472 173 13.0 4.6 1.7 0.2 31.7 11.8
End of study 490 275 13.3 4.0 1.7 0.2 31.2 10.5
Data are meanSD. Mean ferritin levels increased by 17.3%.
Table 2. Haematological parameters (haemoglobin and red cell indices [MCV, MCH, MCHC])
Week Hb (g/dl) MCV (fl) MCH (pg) MCHC (g/dl)
Screening 12.1 1.1 95.0 6.8 31.3 2.6 33.0 1.2
Week 1 12.2 1.1 95.5 6.7 31.4 2.5 32.8 1.0
Week 5 12.2 1.0 95.4 6.1 31.5 2.4 32.9 1.2
Week 9 12.4 1.1 95.6 6.1 31.6 2.4 33.1 1.0
Week 13 12.3 0.9 96.5 6.6 31.8 2.5 32.9 1.2
Week 17 12.4 1.0 96.2 6.0 31.8 2.5 33.1 1.1
Week 21 12.4 0.9 95.9 6.2 31.9 2.5 33.2 1.1
End of study 12.1 1.5 95.9 6.4 31.7 2.4 33.1 1.1
Data are meanSD. Haemoglobin values remained stable and the red cell indices did not change.
Table 3. Monthly dosage of epoetins (standardized values)
Period Darbepoetin alfa (mg) Epoetin alfa (IU) Epoetin beta (IU)
Number of patients n¼ 14 n¼ 13 n¼ 19
Mean baseline (weeks 12 to 1) 221 159 28 578 13 411 36 894 20 404
Weeks 1–4 237 159 24 533 13 405 32 310 20 697
Weeks 5–8 195 122 21 867 14 745 32 619 17 912
Weeks 9–12 179 112 24 533 13 384 32 190 15 069
Weeks 13–16 172 112 26 133 15 829 32 095 15 437
Weeks 17–20 142 89 28 714 17 144 33 368 14 758
Weeks 21–24 136 90 26 769 18 376 33 842 15 643
Data are mean SD. The dosage for the three epoetins decreased by 38.5% [darbepoetin alfa (Aranesp)], 6.3% [epoetin alfa (Eprex)]
and 8.3% [epoetin beta (Recormon)].
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of 50mg weekly. This reduced dosing regimen of iron
sucrose was well tolerated by the patients. The
intention to treat (ITT) population received 1062 iron
sucrose doses, corresponding to a total amount of
53 100mg. Only one adverse event was classified as
possibly related to Venofer by the investigators
(swelling of soft tissue of unclear reason in different
locations). None of the patients died. Hypotensive
episodes were not reported. The mean systolic
and diastolic blood pressures were unchanged prior
to and after the iron sucrose administration through-
out the study (Figure 1).
Discussion
The optimal intravenous iron dose required to main-
tain an iron-replete state in maintenance haemodialysis
patients has not been defined yet. Therefore,
a standardized approach to apply intravenous iron in
iron-replete patients is lacking, and many dialysis
centres have only insufficient treatment concepts
[13,14]. Commonly, iron is applied only when iron
deficiency is overt. Iron is then administered in
relatively large doses, for weeks to months, and
treatment is interrupted until ferritin levels drop
below 100 mg/l. This erratic treatment regime induces
marked fluctuations of haemoglobin levels, and the
subsequent epoetin dosages also need to be adapted
frequently. Since there is a slight and continuous loss
of blood and iron in haemodialysis patients, a better
concept would be to apply intravenous iron as
regularly as possible but in low dosage [9,10].
Our study demonstrates that the regular application
of 50mg of intravenous iron sucrose (Venofer) is able
to maintain and even to improve iron parameters in
iron-replete haemodialysis patients. Additionally, this
regimen allowed to markedly reduce the dosages of
epoetin during the treatment. Therefore, iron sucrose
can safely and conveniently be applied on a weekly
basis. Together with a weekly application of epoetin,
this improves anaemia management considerably by
decreasing epoetin requirement, increasing adherence
by patients and simplifying the application by the
nursing staff.
Other investigators have tested various parenteral
maintenance iron regimes [8–12,15–20]. However, most
studies have been performed in iron-deficient patients
or in patients with functional iron deficiency. Based on
some of these studies, a recommendation of 2–3 g iron
per year was calculated for haemodialysis patients.
Therefore, a weekly 50mg dosing schedule (approxi-
mately 2.5 g per year) would seem to be appropriate
for the majority of haemodialysis patients. Of course,
this treatment scheme has limitations, and it may not
be suitable for patients with bleeding, patients with
inflammation and malnutrition and for patients with
obvious iron deficiency. We speculate, however, that
the regular 50mg weekly dose could be applied to
>80% of the stable haemodialysis patients.
Treatment beyond 6 months, however, would need
monitoring to exclude long-term iron overload. This
risk seems minor though, as many dialysis patients will
eventually need some type of access procedure
(percutaneous transluminal angioplasty or surgery)
with subsequent blood loss, or may have some other
form of bleeding (clotting of dialyser, gastro-intestinal
bleeding). Thus, there will be increased blood loss,
which will again require larger amounts of iron or even
transfusions.
In summary, a weekly 50mg iron sucrose intra-
venous dosing scheme maintains stable iron para-
meters and haemoglobin values in iron-replete
haemodialysis patients. The regular application of
50mg iron sucrose allows considerable epoetin dose
reductions. Low-dose iron sucrose dosing may repre-
sent an optimal approach in treating the continuous
loss of iron in haemodialysis patients.
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